Hemostemix Inc. (CVE:HEM – Get Free Report) passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of C$0.06 and traded as low as C$0.05. Hemostemix shares last traded at C$0.06, with a volume of 75,011 shares trading hands.
Hemostemix Stock Performance
The company has a debt-to-equity ratio of -66.09, a quick ratio of 0.48 and a current ratio of 0.24. The stock’s fifty day moving average is C$0.06 and its two-hundred day moving average is C$0.08. The firm has a market cap of C$11.87 million, a price-to-earnings ratio of -2.07 and a beta of 0.59.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Recommended Stories
- Five stocks we like better than Hemostemix
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
